Cepheid (CPHD) PT Cut to $39 at Leerink Partners

Cepheid (CPHD) Cleared by FDA to Market Xpert TV

Cepheid (NASDAQ: CPHD) announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market Xpert® TV, a qualitative in vitro diagnostic test for accurate and reproducible identification of Trichomoniasis in symptomatic and asymptomatic female patients, using urine, endocervical swab or vaginal swabs collected by the patient in a clinical setting. Xpert TV becomes the 18th test available to run on... More

Needham & Company Downgrades Cepheid (CPHD) to Hold

Needham & Company downgraded Cepheid (NASDAQ: CPHD) from Buy to Hold.

Analyst Mike Matson commented, "CPHD's 3Q15 results were consistent with its 10/13/15 preannouncement. Management reiterated the revenue guidance issued with the preannouncement and, not surprisingly, lowered its EPS guidance (which hadn't been updated with... More

UPDATE: Canaccord Genuity Downgrades Cepheid (CPHD) to Hold

(Updated - October 21, 2015 9:03 AM EDT)

Canaccord Genuity downgraded Cepheid (NASDAQ: CPHD) from Buy to Hold with a price target of $34.00 (from $42.00).

Canaccord Genuity analyst Mark Massaro said, "Cepheid went to great lengths on its Q3 call to affirm its commitment to... More

Evercore ISI Upgrades Cepheid (CPHD) to Hold

Evercore ISI upgraded Cepheid (NASDAQ: CPHD) from Sell to Hold with a price target of $32.50 (from $44.50).

For an analyst ratings summary and ratings history on Cepheid click here. For more ratings news on Cepheid click here.

Shares of Cepheid closed at $32.25 yesterday.

Cepheid (CPHD) Misses Q3 EPS by 1c, Raises FY EPS Guidance

Cepheid (NASDAQ: CPHD) reported Q3 EPS of ($0.32), $0.01 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $126.5 million versus the consensus estimate of $126.81 million.

Cepheid sees FY2015 EPS of ($0.01)-$0.01, versus the consensus of ($0.63). Cepheid sees FY2015 revenue of $537-541... More